Immunicon (NASDAQ:IMMC)
Historical Stock Chart
From Jun 2019 to Jun 2024
Immunicon Corporation (NASDAQ:IMMC) announced today the availability of
a new product portfolio for Fluorescence In-Situ Hybridization (FISH)
testing. The new RF Poseidon™ FISH Probes are
available to the life science and diagnostic clinical laboratories.
FISH probes are used to detect gene amplification, gene rearrangements,
microdeletions, chromosome duplications and other genetic abnormalities. “By
eliminating the repeat sequences in the FISH probes, the RF Poseidon
FISH probes allow for a faster hybridization, reduces background and
provides more crisp signals than current probes,”
stated Leon Terstappen, MD, PhD, Chief Scientific Officer, Immunicon
Corporation. “Additionally, we believe the
faster assays allow scientists and laboratorians the flexibility to
obtain results in about 75% less time than current practices today.”
“The addition of the RF Poseidon FISH probe
portfolio to Immunicon’s products expands our
molecular diagnostics offering to customers,”
said Byron Hewett, President & CEO, Immunicon Corporation. “It
allows Immunicon to fully expand into rare cell testing arenas where we
believe there are increasing medical needs.”
The RF Poseidon FISH Probes are developed using the proprietary
Repeat-Free™ technology developed by
Immunicon and the ULS labeling system developed by Kreatech Diagnostics,
the Netherlands. The FISH probes are sold by Immunicon Corporation in
North America and manufactured and sold by Kreatech Diagnostics in the
rest of the world under an agreement entered into by Immunicon and
Kreatech in April 2007.
Fluorescence In-Situ Hybridization (FISH)
Fluorescence In-Situ Hybridization is a technique used to look at
chromosomes (the parts of the cell that contain genetic information in
the form of DNA) or genes (specific regions of DNA in chromosomes that
make RNA and proteins). Pieces of DNA containing a fluorescent dye are
labeled and added to cells on a glass slide. When viewed under a
fluorescent microscope, parts of chromosomes or genes that bind the
pieces of DNA show up as colored. FISH is routinely used in an
increasing number of molecular diagnostic areas, including disease
diagnosis, therapeutic targeting, drug development, gene mapping and
karyotyping analysis. FISH specifically is used to detect gene
amplification, gene rearrangements, microdeletions, chromosome
duplications and viral infections.
About Immunicon Corporation
Immunicon Corporation is developing and commercializing proprietary
cell- and molecular-based human diagnostic and life science research
products, and is providing certain analytical services to pharmaceutical
and biotechnology companies to assist them in developing new therapeutic
agents, with an initial focus on cancer disease management. Immunicon
has developed platform technologies to identify, count and characterize
a small number of rare cells in blood, such as circulating tumor cells
and circulating endothelial cells that are important in many diseases
and biological processes. Immunicon’s
products and underlying technology platforms also have application in
the clinical development of cancer drugs and in cancer research and may
have applications in other fields of medicine, such as cardiovascular
and infectious diseases. For more information, visit www.immunicon.com
or www.poseidondiagnostics.com.
Forward-Looking Statements
The information contained in this press release includes “forward-looking
statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are often preceded by words such as “hope,”
“may,” “believe,”
“anticipate,” “plan,”
“expect,” “intend,”
“assume,” “will”
and similar expressions. Forward-looking statements contained in this
press release include, among others, statements relating to Immunicon’s
key product and clinical development programs, the anticipated clinical
utility of Immunicon’s products, and other
statements not of historical fact. Immunicon cautions investors not to
place undue reliance on the forward-looking statements contained in this
press release. Forward-looking statements speak only as of the date of
this press release, reflect management’s
current expectations and involve certain factors, such as risks and
uncertainties that may cause actual results to be far different from
those suggested by Immunicon’s
forward-looking statements. These factors include, but are not limited
to, risks and uncertainties associated with adequate financing of
Immunicon to continue as a going-concern; Immunicon’s
dependence on Veridex, LLC, a Johnson & Johnson company; the risks and
uncertainties associated with the arbitration proceeding with Veridex
and the award in favor of Veridex given Immunicon’s
dependence on Veridex; research and development and clinical trial
expenditures; commercialization of Immunicon’s
product candidates; Immunicon’s ability to
use licensed products and to obtain new licenses from third parties;
Immunicon’s ability to manage its growth;
obtaining necessary regulatory approvals; reliance on third party
manufacturers and suppliers; reimbursement by third party payors to
Immunicon’s customers for Immunicon’s
products; risks and uncertainties associated with Immunicon’s
outstanding convertible notes and warrants; compliance with applicable
manufacturing standards; the ability to earn license and milestone
payments under Immunicon’s agreement with
Veridex; retaining key management or scientific personnel; delays in the
development of new products or to planned improvements to Immunicon’s
products; effectiveness of Immunicon’s
products compared to competitors’ products;
protection of Immunicon’s intellectual
property and other proprietary rights; conflicts with the intellectual
property of third parties; product liability lawsuits that may be
brought against Immunicon; labor, contract or technical difficulties;
and competitive pressures in Immunicon’s
industry. These factors are discussed in more detail in Immunicon’s
filings with the Securities and Exchange Commission. Except as required
by law, Immunicon accepts no responsibility for updating the information
contained in this press release beyond the published date, whether as a
result of new information, future events or otherwise, or for
modifications made to this document by Internet or wire services. “Immunicon”
and the Immunicon Corporation logo are registered trademarks of
Immunicon Corporation. Repeat-Free and CellTracks are trademarks of
Immunivest Corporation, a wholly-owned subsidiary of Immunicon
Corporation. All other trademarks or servicemarks appearing herein are
the property of their respective holders. ALL RIGHTS RESERVED.